CSIMarket Company Name, Ticker, Industry, else..
 
Bluebird Bio Inc   (NASDAQ: BLUE)
Other Ticker:  
 
 
Price: $3.9300 $-0.01 -0.254%
Day's High: $3.99 Week Perf: 5.36 %
Day's Low: $ 3.90 30 Day Perf: -44.8 %
Volume (M): 48 52 Wk High: $ 29.80
Volume (M$): $ 190 52 Wk Avg: $13.56
Open: $3.92 52 Wk Low: $3.56



 Market Capitalization (Millions $) 38
 Shares Outstanding (Millions) 10
 Employees 313
 Revenues (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) -100
 Capital Exp. (TTM) (Millions $) 7

Bluebird Bio Inc
Bluebird Bio Inc. is a biotechnology company that develops gene therapies for severe genetic diseases and cancer. The company is known for its focus on using gene therapy to treat inherited blood disorders, such as beta-thalassemia and sickle cell disease. Bluebird Bio also develops CAR-T cell therapies for various types of cancer. The company's gene therapies involve modifying a patient's own cells to correct or replace the faulty gene responsible for the disease. Bluebird Bio aims to provide long-lasting and potentially curative treatment options for patients suffering from these devastating conditions.


   Company Address: 455 Grand Union Boulevard Somerville 2145 MA
   Company Phone Number: 499-9300   Stock Exchange / Ticker: NASDAQ BLUE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DNA        17.96% 
IMCR   -2.32%    
MRNA   -2.87%    
NVAX   -1.85%    
RGNX        36.18% 
RLAY   -3.52%    
• View Complete Report
   



Business Update

Bluebird Bio Enters New Chapter Strategic Acquisition by Carlyle and SK Capital to Drive Growth Amidst Market Struggles

Published Fri, Feb 21 2025 2:41 PM UTC

Bluebird Bio, Inc. (NASDAQ: BLUE), a biotechnology company known for its innovative approaches to gene therapy, recently announced a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners, LP. This strategic move comes amid a challenging period for Bluebird, as its shares have been trailing the broader market and failing to keep pace w...
Business Update

Long-Term Data Validates Beti-Cel Gene Therapy as Transformative for Beta-Thalassemia Patients,

Published Sat, Dec 7 2024 6:47 PM UTC

Gene Therapy Breakthrough Offers Hope for Beta-Thalassemia Patients SOMERVILLE, Mass. bluebird bio, Inc. (Nasdaq: BLUE) has announced promising long-term follow-up data indicating that betibeglogene autotemcel (commonly known as beti-cel and marketed as ZYNTEGLO) could offer curative potential for patients with beta-thalassemia. This condition, characterized by the need fo...
Business Update

In a significant stride towards enhancing healthcare accessibility, bluebird bio, Inc. (NASDAQ BLUE), a lea...

Published Wed, Dec 4 2024 4:47 PM UTC

Transforming Healthcare Access: Bluebird Bio s Innovative Agreement with CMMI for Sickle Cell Gene Therapy In a significant stride towards enhancing healthcare accessibility, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotechnology company, has announced its collaboration with the Center for Medicare and Medicaid Innovation (CMMI) to implement an outcomes-based agreement f...
Business Update

Bluebird Bio Soars Record Inventory Turnover & Q2 2024 Filing Completion,

Published Mon, Sep 30 2024 12:47 AM UTC

bluebird bio Surges Ahead with Strong Q2 2024 Form 10-Q Filing and Record Inventory Turnover SOMERVILLE, Mass. bluebird bio, Inc. (Nasdaq: BLUE) has thrilling news to share: the successful completion of their Q2 2024 Form 10-Q filing with the Securities and Exchange Commission (SEC). This pivotal milestone not only marks their current SEC periodic reporting obligations, but ...
Business Update

Bluebird Bio A Tale of Tenacity Amidst Trials and Triumphs in Therapeutic Ventures,

Published Sat, Sep 28 2024 12:47 AM UTC

A Chronicle of Progress in the Realm of Therapeutic Innovators: Bluebird Bio?s Recent Triumphs and Trials In the illustrious and often tumultuous arena of pharmaceutical advancements, the annals of bluebird bio, Inc. weave a narrative both compelling and significant. Situated in the industrious heart of Somerville, Massachusetts, this esteemed enterprise has indubitably capt...






Bluebird Bio Inc's Segments

  Bluebird Bio Inc Outlook

On May 9 2024 the Bluebird Bio Inc provided following guidance

bluebird bio Inc. (NASDAQ: BLUE) has reported its first quarter results for 2024, highlighting the Company's operational progress and providing guidance for the year. The company is based in SOMERVILLE, Mass.

Bluebird bio has established a strong foundation in the commercial gene therapy space, with a network of qualified treatment centers (QTCs) that is considered unparalleled. The company has successfully navigated access and reimbursement challenges for patients, and there is a clear demand for their therapies from both patients and healthcare providers.

These achievements have positioned bluebird bio as a leader in the gene therapy industry, with a promising outlook for the future. The com...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com